Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized controlled study of dapagliflozin for reversal of newly diagnosed type 2 diabetes mellitus
ChiCTR2100043770Phase 4Recruiting
- Sponsor
- Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: Reverse rate. Started Mar 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100043770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043770.